Multikine (Leukocyte Interleukin, Injection)
Advanced Primary Head and Neck Cancer
Phase 3Completed; Preparing BLA/NDA
Key Facts
Indication
Advanced Primary Head and Neck Cancer
Phase
Phase 3
Status
Completed; Preparing BLA/NDA
Company
About CEL-SCI
CEL-SCI is a long-standing, publicly-traded biotech focused on developing Multikine, a first-in-class neoadjuvant immunotherapy for advanced primary head and neck cancer. The company's core strategy is predicated on administering immunotherapy when the patient's immune system is most intact, a paradigm validated by a large, global Phase 3 trial that demonstrated a significant 14.1% absolute overall survival benefit in a key treatment arm. Having completed this pivotal study, CEL-SCI's primary objective is to secure regulatory approval via a BLA/NDA submission, aiming to establish a new standard of care in a significant unmet medical need.
View full company profile